Q4 Earnings Forecast for SRPT Issued By William Blair

Sarepta Therapeutics, Inc. (NASDAQ:SRPT) – Analysts at William Blair issued their Q4 2025 EPS estimates for shares of Sarepta Therapeutics in a report released on Monday, January 27th. William Blair analyst S. Corwin expects that the biotechnology company will earn $3.60 per share for the quarter. The consensus estimate for Sarepta Therapeutics’ current full-year earnings is $2.49 per share.

Other equities analysts have also recently issued research reports about the company. HC Wainwright reiterated a “sell” rating and issued a $75.00 target price on shares of Sarepta Therapeutics in a report on Thursday. Needham & Company LLC reaffirmed a “buy” rating and set a $202.00 price objective on shares of Sarepta Therapeutics in a research note on Monday. Jefferies Financial Group initiated coverage on shares of Sarepta Therapeutics in a research note on Monday, October 21st. They issued a “buy” rating and a $165.00 target price on the stock. Piper Sandler lowered their target price on shares of Sarepta Therapeutics from $200.00 to $182.00 and set an “overweight” rating for the company in a report on Wednesday, November 27th. Finally, Guggenheim upped their price target on shares of Sarepta Therapeutics from $148.00 to $150.00 and gave the company a “buy” rating in a report on Thursday, November 7th. One research analyst has rated the stock with a sell rating, two have given a hold rating, nineteen have issued a buy rating and one has given a strong buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average target price of $178.71.

Sarepta Therapeutics Trading Down 1.8 %

Shares of NASDAQ SRPT opened at $115.45 on Thursday. Sarepta Therapeutics has a 1-year low of $102.15 and a 1-year high of $173.25. The company has a debt-to-equity ratio of 0.93, a current ratio of 3.84 and a quick ratio of 3.03. The business’s 50 day moving average is $122.73 and its two-hundred day moving average is $127.59. The stock has a market capitalization of $11.03 billion, a P/E ratio of 92.36 and a beta of 0.77.

Hedge Funds Weigh In On Sarepta Therapeutics

A number of large investors have recently made changes to their positions in the business. Van ECK Associates Corp boosted its position in shares of Sarepta Therapeutics by 24.4% in the 4th quarter. Van ECK Associates Corp now owns 84,834 shares of the biotechnology company’s stock worth $10,315,000 after purchasing an additional 16,658 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Sarepta Therapeutics by 16,717.7% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 85,434 shares of the biotechnology company’s stock valued at $10,602,000 after buying an additional 84,926 shares during the last quarter. Louisiana State Employees Retirement System raised its stake in Sarepta Therapeutics by 0.4% in the fourth quarter. Louisiana State Employees Retirement System now owns 26,500 shares of the biotechnology company’s stock valued at $3,222,000 after buying an additional 100 shares during the last quarter. Sovran Advisors LLC acquired a new stake in Sarepta Therapeutics in the fourth quarter worth about $3,210,000. Finally, Newbridge Financial Services Group Inc. purchased a new stake in shares of Sarepta Therapeutics during the fourth quarter worth about $36,000. 86.68% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Sarepta Therapeutics news, Director Hans Lennart Rudolf Wigzell sold 10,500 shares of the business’s stock in a transaction dated Thursday, December 12th. The shares were sold at an average price of $124.84, for a total value of $1,310,820.00. Following the completion of the transaction, the director now directly owns 22,840 shares in the company, valued at approximately $2,851,345.60. The trade was a 31.49 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Kathryn Jean Boor sold 1,636 shares of the stock in a transaction dated Thursday, December 5th. The shares were sold at an average price of $125.55, for a total transaction of $205,399.80. Following the sale, the director now directly owns 5,880 shares of the company’s stock, valued at approximately $738,234. The trade was a 21.77 % decrease in their ownership of the stock. The disclosure for this sale can be found here. 7.70% of the stock is currently owned by insiders.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, gene therapies, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 injection to treat duchenne muscular dystrophy (duchenne) in patients with confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of duchenne in patients with confirmed mutation of the dystrophin gene; and ELEVIDYS, an adeno-associated virus based gene therapy for the treatment of ambulatory pediatric patients aged 4 through 5 years with duchenne with a confirmed mutation in the duchenne gene.